Clinical trial
Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in…
NCT00426777 · CMX Research, Other · Completed
Key facts
| NCT number | NCT00426777 |
|---|---|
| Title | Efficacy Study of Risedronate to Prevent Cancer Treatment-Induced Bone Loss in Prostate Cancer |
| Official title | A Randomized, Single-blind, Placebo-controlled, Multicentre Study to Evaluate the Effect of Risedronate and Placebo on Bone Mineral Density in Men Undergoing Androgen Deprivation Therapy With Leuprolide Acetate |
| Lead sponsor | CMX Research, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | risedronate, Control |
| Enrollment | 160 |
| Start date | Jan 1, 2007 |
| Primary completion | Jan 1, 2009 |
| Completion | Feb 1, 2009 |
| First posted | Jan 25, 2007 |
| Last update posted | Feb 3, 2012 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: